NEW YORK-- Orthopedic device maker NuVasive Inc. forecast disappointing third-quarter revenue on Wednesday, and its shares plunged in after-hours trading. NuVasive said it expects about $147 million in revenue in the third quarter. Shares of NuVasive dropped $5.63, or 24.9 percent, to $16.99 in late trading.

Health-care and pharmaceutical stocks are facing a great amount of uncertainty in the wake of health-care reform. Rosanne Ott, co-portfolio manager at Alger Health Sciences Fund, offered CNBC her investment advice and favorite stocks.

Stocks declined on Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month. Some analysts said these fits and starts are just the market cooling down after a runup of 30 percent since the market hit a 12-year low in early March. Read and listen to what the experts had to say...